Intranasal Azelastine for Seasonal Allergic Rhinitis in Chronic Kidney Disease
ASTEPRO (azelastine hydrochloride) nasal spray is indicated for relief of symptoms of seasonal allergic rhinitis in patients age ≥6 years. [1] ASTEPRO has no listed contraindications. [1]
Indication Alignment With Seasonal Allergic Rhinitis
ASTEPRO is indicated for seasonal allergic rhinitis symptom relief. [1] Single-kidney status does not alter the labeled allergic rhinitis indication. [1]
Renal Impairment Pharmacokinetics Considerations
Renal impairment increases azelastine exposure after oral dosing. [1] Renal insufficiency defined as creatinine clearance <50 mL/min resulted in 70% to 75% higher Cmax and AUC after oral, single-dose azelastine compared with healthy subjects. [1] After intranasal dosing, systemic bioavailability is approximately 40%. [1]
Safety Expectations for the Nasal Route
Intranasal administration results in measurable but limited systemic exposure relative to oral dosing, based on labeled systemic bioavailability after intranasal administration. [1] No contraindications are listed for use in renal impairment in the labeled indication and precautions sections. [1]
Treatment Selection Algorithm
First-line options for seasonal allergic rhinitis include intranasal antihistamines such as azelastine hydrochloride nasal spray. [1] When symptom control requires combination therapy, intranasal antihistamine plus intranasal corticosteroid strategies are used in allergic rhinitis care, but regimen selection depends on symptom severity and comorbidities. [1]
Initiation Thresholds and Dosing
ASTEPRO dosing for seasonal allergic rhinitis in adults and adolescents age ≥12 years is 1 or 2 sprays per nostril twice daily, or 2 sprays per nostril once daily (0.1% formulation, 137 mcg per spray). [1] ASTEPRO should be primed before initial use and when not used for 3 or more days. [1]
Common Pitfalls to Avoid
Somnolence can occur after ASTEPRO administration. [1] Hazardous occupations requiring complete mental alertness and motor coordination should be avoided after ASTEPRO dosing. [1] Concurrent use of ASTEPRO with alcohol or other central nervous system depressants should be avoided due to additional alertness impairment. [1]
Clinical Monitoring Considerations in Chronic Kidney Disease
Monitoring for adverse effects that affect the central nervous system (somnolence) and nasal tolerability (e.g., dysgeusia, nasal discomfort, epistaxis) is appropriate during therapy. [1] Renal function parameters are not specifically listed as dose-adjustment targets in the labeled renal impairment section for ASTEPRO. [1]
Conclusion on Appropriateness
ASTEPRO is appropriate for seasonal allergic rhinitis based on the labeled indication and lack of contraindications. [1] Renal impairment mainly affects azelastine exposure after oral dosing, while intranasal therapy has limited systemic exposure, supporting use without labeled renal dose adjustment. [1]